SAN DIEGO, May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May.(PRNewsfoto/Neurocrine Biosciences, Inc.) Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the BofA Securities 2025 Health Care …
SAN JOSE, Calif., May 06, 2025--(BUSINESS WIRE)--After market close on Thursday, May 29, 2025, NetApp (NASDAQ: NTAP) will announce financial results for the fourth quarter and fiscal year 2025 which ended April 25, 2025. NetApp executive management will host a conference call Webcast at …
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephience launch activities progressing well – – Strong cash position of …
Ultragenyx Pharmaceutical Inc. First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue …
First quarter net income of $0.67 per diluted share and adjusted operating income of $0.70 per diluted share First quarter 2025 highlights compared to first quarter 2024, unless otherwise noted:(1) Net income increased 31% to $17.7 million.Net investment income increased 44% to $23.5 million.Combined …
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 …
CHICAGO, May 06, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the …
Arcutis Biotherapeutics, Inc. Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring …
First quarter 2025 GAAP diluted earnings per share of $1.73 First quarter 2025 adjusted airline-only diluted earnings per share of $2.11(1)(2) First quarter 2025 adjusted diluted earnings per share of $1.81(1)(2)(3) LAS VEGAS, May 6, 2025 /PRNewswire/ -- Allegiant Travel Company (NASDAQ: ALGT) today …
AUSTIN, Texas, May 06, 2025--(BUSINESS WIRE)--Cirrus Logic, Inc. (NASDAQ: CRUS) today posted on its website at investor.cirrus.com the quarterly shareholder letter that contains the complete financial results for the fourth quarter and full fiscal year 2025, which ended March 29, 2025, as well as …